What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SRN001 is an investigational drug administered at doses of 45 mg, 90 mg, or 180 mg depending on cohort.”In the company’s words, NCT07407543 on ClinicalTrials.gov
- Tested for
- Idiopathic Pulmonary Fibrosis
- Main trialPhase 1
- “To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of SRN001 in healthy adult volunteers.”In the company’s words, NCT07407543 on ClinicalTrials.gov
Other drugs for Idiopathic Pulmonary Fibrosis
- SC1011JOYO Pharma · Phase 2/3
- NerandomilastBoehringer Ingelheim · Phase 3
- NAL ERTrevi Therapeutics · Phase 3
- AK3280Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3
- TDI01Beijing Tide Pharmaceutical Co., Ltd · Phase 3
- INS018_055InSilico Medicine Hong Kong Limited · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Oct 2026 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males | |
| Phase 1Completed | 15 Mar 2024 | The First-in-human Study of SRN-001 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026